愛康醫療(01789.HK)擬斥資4020萬美元收購北京理貝爾生物工程研究所全部股權
格隆匯4月6日丨愛康醫療(01789.HK)發佈公告,2020年4月6日,公司間接全資附屬公司愛康醫療國際有限公司作為買方與美敦力康輝控股(中國)公司訂立購股協議,據此,賣方同意出售北京理貝爾生物工程研究所有限公司全部股權,總代價為4020萬美元(可予調整),並須以現金結算。
目標公司北京理貝爾生物工程研究所有限公司為一間根據中國法律成立的有限公司,由賣方全資擁有,為於中國從事生產、銷售及研究骨科植入物及手術器械的公司。
公告表示,目標公司是一傢俱有歷史和品牌知名度的中國骨科企業,在設計開發及製造骨科植入物及手術工具方面擁有專業的知識和技術。董事會認為,成為中國骨科領域的領導者之一是集團的長期戰略目標,收購目標公司與集團的這一戰略目標一致,並將於未來提高集團的整體財務表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.